KLH 2109

Drug Profile

KLH 2109

Alternative Names: KLH-2109; OBE 2109

Latest Information Update: 30 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Kissei Pharmaceutical; ObsEva
  • Class Antihormones
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Uterine leiomyoma
  • Phase II Endometriosis

Most Recent Events

  • 07 Jun 2017 Efficacy data from a phase I clinical trial in Endometriosis released by ObsEva
  • 07 Jun 2017 ObsEva completes a phase I clinical trial for Endometriosis in United Kingdom
  • 25 Apr 2017 Phase-III clinical trials in Uterine leiomyoma (Combination therapy) in USA (PO) (NCT03070899)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top